Bayer AG reported positive topline results from the third and final Phase III clinical trial of its non-hormonal treatment for vasomotor symptoms (VMS) associated with menopause on 19 March, declaring that it will now seek approvals for elinzanetant in multiple markets. This will pit the drug against a rival product, Astellas Pharma, Inc.’s Veozah (fezolinetant), which to date has seen sluggish sales that prompted the Japanese drug maker to lower its forecast for the product.
Bayer Ready To File Elinzanetant After It Clears Third Phase III Hurdle
Will Compete With Sluggish Astellas Competitor
Bayer will submit its non-hormonal treatment for vasomotor symptoms associated with menopause for approvals this year, still eyeing €1bn-plus in peak sales despite a rival’s slow start.
